NCT02569489 2022-07-18
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
HUYABIO International, LLC.
Phase 1 Withdrawn
HUYABIO International, LLC.
NKGen Biotech, Inc.
iOMEDICO AG
GlaxoSmithKline
Hoffmann-La Roche
GlaxoSmithKline